Patents Examined by Thomas D. Mays
  • Patent number: 4980288
    Abstract: Cloned DNA is mutated by creating a single-stranded target region in a cloned DNA segment, and introducing a mutation into the single-stranded target region by treating the target region with a chemical or biological mutagenizing agent capable of introducing mutations into single-stranded DNA. The mutated target region then is rendered double-stranded and a microorganism is transformed with the mutated double-stranded DNA present in an expression vector. The transformed microorganism is cultivated under conditions wherein the mutated DNA is expressed to form an expression product, and the expression product is screened to identify a desired mutation in the DNA segment. Mutant subtilisins of enhanced thermal stability are also disclosed.
    Type: Grant
    Filed: December 14, 1987
    Date of Patent: December 25, 1990
    Assignee: Genex Corporation
    Inventors: Philip N. Bryan, Michele L. Rollence, Michael W. Pantoliano
  • Patent number: 4977247
    Abstract: Immobilized IgG binding proteins and the use thereof to effect affinity chromatography and separate the subclasses of IgG. Disclosed are cysteine-containing IgG binding proteins which have high binding capacity for human IgG and mouse monoclonal IgG.
    Type: Grant
    Filed: May 19, 1989
    Date of Patent: December 11, 1990
    Assignee: Genex Corporation
    Inventors: Stephen R. Fahnestock, Timothy Lee, Marie H. Wroble
  • Patent number: 4975374
    Abstract: The invention relates to a mutant glutamine synthetase (GS) enzyme which is resistant to inhibition by herbicidal GS inhibitors, such as phosphinothricin (PPT), genetic sequences coding therefor, plants cells and prokaryotes transformed with the genetic sequences, and herbicidal GS inhibitor-resistant plant cells and plants.
    Type: Grant
    Filed: February 4, 1987
    Date of Patent: December 4, 1990
    Assignee: The General Hospital Corporation
    Inventors: Howard Goodman, Shiladitya DasSarma, Edmund Tischer, Theresa K. Peterman
  • Patent number: 4970296
    Abstract: Disclosed is a heterodimeric T lymphocyte receptor comprising an alpha and a beta subunit. Each subunit consists of a signal peptide, variable, joining, constant, transmembrane, and cytoplasmic regions. The two subunits are connected by a disulfide bond between cysteine residues located between the constant and transmembrane region.The structure, amino acid, and nucleotide sequence of the lymphocyte receptor were determined using CDNA clones derived from a functional murine cytotoxic T lymphocyte clone. The genes corresponding to these cDNA are expressed and rearranged specifically in T cells and have significant sequence homologies to immunoglobulin V and C genes.Both the T cell receptor protein and its subunits may be produced from the cDNA clones. The protein molecules may be further used for the production of T-cell clone specific antibodies.
    Type: Grant
    Filed: July 27, 1989
    Date of Patent: November 13, 1990
    Assignees: Massachusetts Institute of Technology, Board of Trustees of Leland Stanford Jr. University
    Inventors: Haruo Saito, David M. Kranz, Herman N. Eisen, Susumu Tonegawa
  • Patent number: 4968626
    Abstract: Genomic and cDNA sequences coding for a protein having substantially the same biological activity as human protein C are disclosed. Recombinant plasmids and bacteriophage transfer vectors incorporating these sequences are also disclosed.
    Type: Grant
    Filed: August 15, 1985
    Date of Patent: November 6, 1990
    Assignee: Board of Reagents of the University of Washington
    Inventors: Donald C. Foster, Earl W. Davie
  • Patent number: 4966849
    Abstract: DNA sequences encoding a protein having angiogenic activity and mutated DNA sequences encoding a protein having decreased angiogenic activity are disclosed. Expression vectors containing these wild-type or mutated sequences are introduced into host cells and direct the production of wild-type or mutant angiogenic proteins. Proteins produced according to the invention are useful in the diagnosis of malignancies, for promoting wound healing, and for other diagnostic and therapeutic purposes. Mutant proteins produced according to the invention are useful therapeutic compositions as angiogensis inhibitors, which may retard tumor growth by inhibiting the development of a hemovascular network.
    Type: Grant
    Filed: February 2, 1989
    Date of Patent: October 30, 1990
    Assignee: President and Fellows of Harvard College
    Inventors: Bert L. Vallee, Kotoku Kurachi
  • Patent number: 4965197
    Abstract: A coryneform expression and secretion system for homologous and heterologous genes consisting of the host, nucleotide sequences encoding a protein of interest, signals for expression and, optionally, targeting signals which direct membrane anchoring and for secretion and processing of the expressed protein. Regulatory signals may be utilized to control the rate and extent of expression and secretion. The system may further include compounds such as ionophores for altering the membrane transport of the host. The host itself may be mutated to alter transport, for example, by decreasing the mycolic acid content of Corynebacteria species.The preferred host is a Corynebacterium although other coryneforms deficient in extracellular protease production may also be used. C. glutamicum is used as a model organism for the secretion system.
    Type: Grant
    Filed: December 5, 1989
    Date of Patent: October 23, 1990
    Assignee: Massachusetts Institute of Technology
    Inventors: Wolfgang Liebl, Anthony J. Sinskey
  • Patent number: 4963487
    Abstract: Disclosed is a method and linear DNA fragments for use in the deletion of a gene from a bacteria with a single step procedure that is applicable to any essential or nonessential gene which has been cloned. Chromosomal deletions are constructed by transformation of a cell strain with linear DNA fragments containing a locus for resistance to an antibiotic, or any other gene allowing for rapid phenotypic selection, flanked by sequences homologous to closely spaced regions on the cell chromosome on either side of the gene to be deleted, in combination with the immediate subsequent deletion or inactivation of the recA gene. By selecting for a double-crossover event between the homologous sequences, shown by the antibiotic resistance or other detectable phenotype, a chromosome disruption can be selected for which has effectively deleted an entire gene.
    Type: Grant
    Filed: September 14, 1987
    Date of Patent: October 16, 1990
    Assignee: Massachusetts Institute of Technology
    Inventor: Paul R. Schimmel
  • Patent number: 4960704
    Abstract: A modified hygromycin B resistance-conferring gene either alone or in translational reading phase with a gene or portion of a gene is disclosed. The invention further comprises recombinant DNA cloning vectors and transformants of the aforementioned DNA.
    Type: Grant
    Filed: May 31, 1988
    Date of Patent: October 2, 1990
    Assignee: Eli Lilly and Company
    Inventors: Thomas D. Ingolia, Kevin R. Kaster, R. Nagaraja Rao
  • Patent number: 4959318
    Abstract: Genomic and cDNA sequences coding for a protein having substantially the same biological activity as human protein C and recombinant transfer vectors comprising these sequences are disclosed.Methods are disclosed for producing a protein which has substantially the same biological activity as human protein C. The protein, which may be in the form of activated protein C, is produced by mammalian host cells transfected with a plasmid capable of integration in mammalian host cell DNA. The plasmid includes a promoter followed downstream by a nucleotide sequence which encodes a protein having substantially the same structure and/or activity as human protein C, the nucleotide sequence being followed downstream by a polyadenylation signal.
    Type: Grant
    Filed: October 29, 1986
    Date of Patent: September 25, 1990
    Assignee: ZymoGenetics, Inc.
    Inventors: Donald C. Foster, Mark J. Murray, Kathleen L. Berkner
  • Patent number: 4957869
    Abstract: Disclosed are peptides comprising the amino acidsAsp-Arg-Ala-X-Gly-Gln-Pro-Ala-Glywherein X represents Asp or Ala, said peptides eleciting antibodies against the P. vivax circumsporozoite protein. Also disclosed are DNA sequences coding for such peptides.
    Type: Grant
    Filed: April 5, 1988
    Date of Patent: September 18, 1990
    Assignee: New York University
    Inventors: David E. Arnot, Vincenzo Enea, Ruth S. Nussenzweig, Victor N. Nussenzweig
  • Patent number: 4956296
    Abstract: A cloned gene encoding Protein G, or functionally active portions thereof, vectors containing the cloned gene, and microorganisms transformed by those vectors are disclosed.
    Type: Grant
    Filed: June 20, 1988
    Date of Patent: September 11, 1990
    Assignee: Genex Corporation
    Inventor: Stephen R. Fahnestock
  • Patent number: 4954618
    Abstract: A cloned gene encoding Protein G, or functionally active portions thereof, vectors containing the cloned gene, and microorganisms transformed by those vectors are disclosed.
    Type: Grant
    Filed: March 15, 1989
    Date of Patent: September 4, 1990
    Assignee: Genex Corporation
    Inventor: Stephen R. Fahnestock
  • Patent number: 4952682
    Abstract: A novel highly effective prokaryotic expression system is exemplified specifically by being used to produce the useful enzyme .beta.-glucuronidase (BG). This system uses a hybrid plasmid comprising BG gene promoter DNA. The level of expression of BG by an E. coli K-12 derivative host is in the 50% of total cellular protein range. The invention expression system also can be used to express other useful proteins, as disclosed herein.
    Type: Grant
    Filed: September 30, 1988
    Date of Patent: August 28, 1990
    Assignee: Repligen Corporation
    Inventors: Algis Anilionis, John L. Palmer
  • Patent number: 4950603
    Abstract: DNA compounds encoding the Streptomyces lipmanii isopenicillin N synthetase (IPNS) gene are useful for constructing a variety of recombinant DNA vectors. The vectors are useful in producing IPNS in a wide variety of host cells, such as Streptomyces, Penicillium, and Cephalosporium. DNA compounds encoding the transcription and translation activating sequence and transcription termination sequence of the S. lipmanii IPNS gene are also useful in the construction of expression vectors, especially Streptomyces expression vectors. The S. lipmanii IPNS gene can be isolated from plasmid pOGO239, available from the Northern Regional Research Center under accession number NRRL B-18250.
    Type: Grant
    Filed: November 2, 1987
    Date of Patent: August 21, 1990
    Assignee: Eli Lilly and Company
    Inventors: Thomas D. Ingolia, Barbara J. Weigel
  • Patent number: 4946786
    Abstract: 1Method for production of a composition consisting essentially of a T7-type DNA polymerase and thioredoxin. The method includes culturing a cell containing plasmid DNA encoding a T7-type DNA polymerase to express the T7-type DNA polymerase from the plasmid DNA, and purifying the T7-type DNA polymerase expressed from the cell to reduce the exonuclease activity associated with the T7-type DNA polymerase compared to the level of exonuclease activity associated with a corresponding naturally-occurring T7-type DNA polymerase.
    Type: Grant
    Filed: March 1, 1990
    Date of Patent: August 7, 1990
    Assignee: President and Fellows of Harvard College
    Inventors: Stanley Tabor, Charles C. Richardson
  • Patent number: 4942130
    Type: Grant
    Filed: December 14, 1987
    Date of Patent: July 17, 1990
    Assignee: President & Fellows of Harvard College
    Inventors: Stanley Tabor, Charles C. Richardson
  • Patent number: 4929559
    Abstract: One of the E. coli strains of the Clarke and Carbon collection [Cell, 9, 91-99] has been found to contain a plasmid which we have isolated and termed pLC3-13, which contains genetic information coding for prolipoprotein signal peptidase. A 4.3 kb fragment containing this genetic information has been prepared, other plasmids have been prepared containing at least this fragment and strains of E. coli have been transformed thereby.
    Type: Grant
    Filed: February 23, 1988
    Date of Patent: May 29, 1990
    Assignee: Sankyo Company Limited
    Inventors: Shoji Mizushima, Hideo Yamagata
  • Patent number: 4923799
    Abstract: The invention provides a nucleic acid having a sequence which encodes a polypeptide that is at least part of a T cell antigen receptor. This encoded sequence is about 936 nucleotides in length and preferably is a human T cell antigen receptor. The nucleic acid sequence of one embodiment of the invention is shown in FIG. 3.The nucleic acid sequence may be used as a probe to determine whether an unknown cell, e.g., a tumor cell, is a T cell.Polypeptides encoded by the nucleic acid sequence include about 312 amino acids and are at least part of a T cell antigen receptor. They include at least one sequence which over 21 contiguous amino acids has greater than about 35% homology with mouse and human immunoglobin .lambda. light chains.Antibody to the polypeptide may be prepared and used to identify T cell antigen receptor and to determine whether an unknown cell, e.g., a tumor cell, is a T cell.
    Type: Grant
    Filed: November 9, 1987
    Date of Patent: May 8, 1990
    Assignee: The Ontario Cancer Institute
    Inventor: Tak W. Mak
  • Patent number: 4921794
    Abstract: This invention relates to T7-type DNA polymerases and methods for amplification of DNA, for example by polymerase chain reaction.
    Type: Grant
    Filed: December 5, 1988
    Date of Patent: May 1, 1990
    Assignee: President and Fellows of Harvard College
    Inventors: Stanley Tabor, Charles C. Richardson